Kodiak Sciences Inc., a biotech company focused on retinal diseases, announced that CEO Victor Perlroth will present at three major investor conferences in November and December 2026, including Jefferies Global Healthcare, UBS Global Biopharma, and Evercore Healthcare conferences. Kodiak is developing late-stage clinical programs targeting retinal diseases like wet AMD and diabetic retinopathy, with key data from Phase 3 studies expected by mid-2027. These presentations will update investors on the company’s progress in developing transformative retinal therapeutics addressing a $15 billion market.
Kodiak Sciences' upcoming investor presentations come as 86 of 150 Health-sector US stocks on Pluang rose today. For readers following this sector, here is Pluang's market snapshot as of Nov 12, 2026 05:11 WIB: Axogen Inc (AXGN) gained 15.03% to USD 58.54 with 95% buy orders and a typical hold time of 18 days; Ginkgo Bioworks Holdings (DNA) fell 13.49% to USD 10.39 with 96% buy orders and a 9-day hold time; Butterfly Network Inc (BFLY) rose 9.14% to USD 7.11 with a 16-day hold time.
Digital Turbine delayed its Q2 2027 financial results, then restated prior financials due to $3.5 million in understated revenue share expenses. This caused the stock to drop sharply, falling over 35% after the restatement. A law firm is investigatin...
AtlasClear Holdings announced the signing of its ninth correspondent broker-dealer agreement through its subsidiary AtlasClearing, contributing to an 85% revenue increase to $20.1 million in fiscal 2026. This growth occurred before significant revenu...
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
